Literature DB >> 19398574

Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients.

Iyad Sultan1, Ibrahim Qaddoumi, Sameer Yaser, Carlos Rodriguez-Galindo, Andrea Ferrari.   

Abstract

PURPOSE: To compare clinical features and outcomes of adults and children reported to have rhabdomyosarcoma. PATIENTS AND METHODS: We analyzed data from 1,071 adults (age > 19 years) and 1,529 children (age < or = 19 years) reported in the public-access Surveillance, Epidemiology and End Results database as having rhabdomyosarcoma, diagnosed from 1973 to 2005. Survival estimates were determined using survival time with the end point being death from any cause.
RESULTS: Adults with rhabdomyosarcoma had significantly worse outcome than children (5-year overall survival rates, 27% +/- 1.4% and 61% +/- 1.4%, respectively; P < .0001). Tumors in adults were more likely to be at an unfavorable site (65% v 55%; P < .0001) and to have histologies that are unusual during childhood, particularly the pleomorphic subtype (19%) and not otherwise specified (43%). Regional and distant spread was not more frequent in adults. Adults had significantly worse outcome than children with similar tumors. The most significant difference was in localized disease; 5-year survival estimates were 82% +/- 2.0% for children and 47% +/- 2.9% for adults (P < .0001). Multivariate analysis showed that age, histologic subtype, primary site location, stage, and local control with surgery and/or radiation were significant predictors of survival. However, alveolar subtype and unfavorable primary site lost significance when analysis was restricted to adults.
CONCLUSION: Adults reported to have rhabdomyosarcoma had worse survival than children with similar tumors. Predictors of poor outcome in children were valid in adults except for alveolar histology and unfavorable tumor site.

Entities:  

Mesh:

Year:  2009        PMID: 19398574     DOI: 10.1200/JCO.2008.19.7483

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  113 in total

Review 1.  Rhabdomyosarcoma: current challenges and their implications for developing therapies.

Authors:  Simone Hettmer; Zhizhong Li; Andrew N Billin; Frederic G Barr; D D W Cornelison; Alan R Ehrlich; Denis C Guttridge; Andrea Hayes-Jordan; Lee J Helman; Peter J Houghton; Javed Khan; David M Langenau; Corinne M Linardic; Ranadip Pal; Terence A Partridge; Grace K Pavlath; Rossella Rota; Beat W Schäfer; Janet Shipley; Bruce Stillman; Leonard H Wexler; Amy J Wagers; Charles Keller
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

2.  Oral low-dose chemotherapy: successful treatment of an alveolar rhabdomyosarcoma during pregnancy.

Authors:  Meinolf Siepermann; Ewa Koscielniak; Tobias Dantonello; Dirk Klee; Joachim Boos; Barbara Krefeld; Arndt Borkhardt; Thomas Hoehn; Alexzander Asea; Rüdiger Wessalowski
Journal:  Pediatr Blood Cancer       Date:  2011-01-16       Impact factor: 3.167

Review 3.  Multimodality imaging of adult rhabdomyosarcoma: the added value of hybrid imaging.

Authors:  Nicolò Gennaro; Andrea Marrari; Salvatore Lorenzo Renne; Ferdinando Carlo Maria Cananzi; Vittorio Lorenzo Quagliuolo; Lucia Di Brina; Marta Scorsetti; Giovanna Pepe; Arturo Chiti; Armando Santoro; Luca Balzarini; Letterio Salvatore Politi; Alexia Francesca Bertuzzi
Journal:  Br J Radiol       Date:  2020-06-26       Impact factor: 3.039

4.  Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors.

Authors:  Catherine J Drummond; Jason A Hanna; Matthew R Garcia; Daniel J Devine; Alana J Heyrana; David Finkelstein; Jerold E Rehg; Mark E Hatley
Journal:  Cancer Cell       Date:  2018-01-08       Impact factor: 31.743

5.  Orbital rhabdomyosarcomas: A review.

Authors:  Lama Jurdy; Johanus H M Merks; Bradly R Pieters; Maarten P Mourits; Roel J H M Kloos; Simone D Strackee; Peerooz Saeed
Journal:  Saudi J Ophthalmol       Date:  2013-07

6.  Testosterone-mediated activation of androgenic signalling sustains in vitro the transformed and radioresistant phenotype of rhabdomyosarcoma cell lines.

Authors:  S Giannattasio; F Megiorni; V Di Nisio; A Del Fattore; R Fontanella; S Camero; C Antinozzi; C Festuccia; G L Gravina; S Cecconi; C Dominici; L Di Luigi; C Ciccarelli; P De Cesaris; A Riccioli; B M Zani; A Lenzi; R G Pestell; A Filippini; C Crescioli; V Tombolini; F Marampon
Journal:  J Endocrinol Invest       Date:  2018-05-22       Impact factor: 4.256

7.  Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy.

Authors:  Yuki Kojima; Kenji Hashimoto; Masashi Ando; Kan Yonemori; Akihiro Hirakawa; Makoto Kodaira; Mayu Yunokawa; Chikako Shimizu; Kenji Tamura; Noriyuki Katsumata; Ako Hosono; Atsushi Makimoto; Yasuhiro Fujiwara
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-23       Impact factor: 4.553

Review 8.  Rhabdomyosarcoma in adults: new perspectives on therapy.

Authors:  Catalina Ruiz-Mesa; John M Goldberg; Alvaro J Coronado Munoz; Sarah N Dumont; Jonathan C Trent
Journal:  Curr Treat Options Oncol       Date:  2015-06

Review 9.  Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas.

Authors:  Douglas S Hawkins; Sheri L Spunt; Stephen X Skapek
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

10.  Unusual association of alveolar rhabdomyosarcoma with pancreatic metastasis: emerging role of PET-CT in tumor staging.

Authors:  Priyanka Jha; Andreas M J Frölich; Beth McCarville; Oscar M Navarro; Paul Babyn; Robert Goldsby; Heike Daldrup-Link
Journal:  Pediatr Radiol       Date:  2010-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.